Fundraising FoxACORN BIOVENTURES — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)inDylan Hartley(Executive Officer)inWendy Johnson(Executive Officer)Nicholas A. Saccomano(President and Chief Executive Officer and Director)
Board seatIsaac Manke· per SEC Form D
Co-investorsAccess BiotechnologyBoulder VenturesRiverVest Venture PartnersAbingworthNew Enterprise Associates (NEA)Novo Holdings
Additive provides a GenAI tool that extracts tax data from K-1, K-3, and related forms (including state forms, 199A, 926, and others), converting PDF tax packages into Excel workpapers or JSON via a web app, Excel add-in, or API.
AI & Machine LearningFintechSaaS
Venky Iyer(Founder)in
Co-investorsMantis CapitalAM VenturesBreakthrough VictoriaElad GilFred EhrsamImmad Akhund+2 more
Genero is a platform that connects marketers with independent creative talent and production partners on demand.
B2B MarketplacesCreator EconomyMarketing TechMelbourne, AU
Andrew Lane(Founder)in
Co-investorsBrick Capital VenturesEllerston Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.